This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +22.98% per year. These returns cover a period from January 1, 1988 through April 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
pharmaceuticals: Archive
Ionis Q1 Earnings and Sales Top Estimates, Stock Gains on Raised '25 View
by Zacks Equity Research
IONS reports better-than-expected first-quarter results. The company raises its sales guidance for 2025 by more than 20% on the back of two new licensing deals.
AZNPositive Net Change NVSNegative Net Change BIIBNegative Net Change IONSNegative Net Change
biotechs earnings medical pharmaceuticals
Madrigal Q1 Earnings Beat, MASH Drug Sales Drive Top Line, Stock Up
by Zacks Equity Research
MDGL stock is rising as it reports better-than-expected first-quarter results, beating earnings and revenue estimates, driven by strong Rezdiffra sales.
BAYRYPositive Net Change BEAMPositive Net Change ADMANegative Net Change MDGLNegative Net Change
biotechnology biotechs earnings medical pharmaceuticals
Jobless Claims Higher; Q1 Earnings from LLY, MCD & More
by Mark Vickery
Last week, 241K Americans filed for unemployment on Initial Jobless Claims, with Continuing Claims touching 1.9 million.
AMZNPositive Net Change AAPLPositive Net Change MAPositive Net Change AMGNNegative Net Change MCDPositive Net Change CVSNegative Net Change WNegative Net Change TWLOPositive Net Change
consumer-discretionary earnings pharmaceuticals
Bausch Health Q1 Earnings and Revenues Miss Estimates, Stock Down
by Zacks Equity Research
BHCs first-quarter 2025 adjusted earnings and revenues miss estimates. Salix performs lower than expected. Stock declines.
BEAMPositive Net Change FOLDNegative Net Change ADMANegative Net Change BHCNegative Net Change
biotechnology biotechs earnings medical pharmaceuticals
UTHR Q1 Earnings & Revenues Beat Estimates on Higher Tyvaso Sales
by Zacks Equity Research
United Therapeutics reports better-than-expected first-quarter 2025 results, beating both earnings and revenue estimates, driven mainly by strong Tyvaso sales.
BAYRYPositive Net Change UTHRNegative Net Change BEAMPositive Net Change ADMANegative Net Change
biotechnology biotechs earnings medical pharmaceuticals
The Zacks Analyst Blog Highlights Amazon, Johnson & Johnson, Cisco Systems and NeurAxis
by Zacks Equity Research
Amazon, Johnson & Johnson, Cisco Systems and NeurAxis are included in this Analyst Blog.
AMZNPositive Net Change JNJNegative Net Change CSCOPositive Net Change NRXSNegative Net Change
pharmaceuticals
Top Stock Reports for Amazon.com, Johnson & Johnson & Cisco Systems
by Mark Vickery
Today's Research Daily features new research reports on 16 major stocks, including Amazon.com, Inc. (AMZN), Johnson & Johnson (JNJ) and Cisco Systems, Inc. (CSCO), as well as a micro-cap NeurAxis, Inc. (NRXS).
AMZNPositive Net Change JNJNegative Net Change CSCOPositive Net Change EFXNegative Net Change AONNegative Net Change CDNSNegative Net Change NRXSNegative Net Change
computers medical pharmaceuticals retail
Buy Hims (HIMS) or Novo Nordisk (NVO) Stock After Partnership Announcement?
by Shaun Pruitt
Medical pioneers Hims & Hers Health (HIMS) and Novo Nordisk (NVO) are making headlines this week after announcing a partnership to expand obesity care in the telehealth space.
NVOPositive Net Change HIMSPositive Net Change LLYNegative Net Change
investing large-cap medical pharmaceuticals
GSK Q1 Earnings Beat, Sales Lag, Stock Gains on Tariff Reassurance
by Zacks Equity Research
GSK reports mixed first-quarter 2025 results. Shares rise in pre-market after it reaffirms guidance and says it is "well positioned" to handle the U.S. tariffs.
SNYNegative Net Change GSKNegative Net Change JNJNegative Net Change VIRNegative Net Change
biotechs earnings medical pharmaceuticals vaccines
Company News for Apr 30, 2025
by Zacks Equity Research
Companies In The News Are: NUE, REGN, PYPL, PFE.
REGNNegative Net Change PFENegative Net Change NUENegative Net Change PYPLNegative Net Change
basic-materials biotechnology business-services pharmaceuticals
Should You Buy, Sell or Hold GILD Stock Post Q1 Earnings Miss?
by Ekta Bagri
GILD is trading down after disappointing first-quarter results. While the fundamentals look solid in the long run, the oncology business is under pressure. We advise investors to remain on the sidelines at current levels.
GSKNegative Net Change MRKNegative Net Change GILDNegative Net Change
biotechnology biotechs medical pharmaceuticals
Buy Pfizer (PFE) Stock for a Rebound After Crushing Q1 EPS Expectations?
by Shaun Pruitt
Pfizer (PFE) shares spiked 3% in Tuesday's trading session as the pharmaceutical giant was able to crush its Q1 earnings expectations.
PFENegative Net Change JNJNegative Net Change NVOPositive Net Change LLYNegative Net Change ABBVNegative Net Change
coronavirus dividend-investing dividends earnings investing medical pharmaceuticals vaccines
Regeneron Stock Falls on Q1 Earnings and Sales Miss, Eylea Sales Down
by Zacks Equity Research
REGN reports lower-than-expected Q1 results. Lead drug Eylea sales plunge in the United States due to competition. Stock down.
REGNNegative Net Change SNYNegative Net Change RHHBYNegative Net Change BAYRYPositive Net Change
biotechnology biotechs earnings medical pharmaceuticals
Pfizer Q1 Earnings Beat Estimates, Several Headwinds Hurt Sales
by Zacks Equity Research
PFE beats first-quarter estimates for earnings but misses the same for sales. It maintains 2025 guidance.
BMYNegative Net Change JNJNegative Net Change PFENegative Net Change BNTXNegative Net Change
pharmaceuticals
Economic Data Deluge
by Zacks Equity Research
Economic Data Deluge.
MSFTPositive Net Change VPositive Net Change PFENegative Net Change HONNegative Net Change SBUXNegative Net Change STXNegative Net Change GMPositive Net Change PYPLNegative Net Change SNAPPositive Net Change SPOTNegative Net Change METANegative Net Change
multi-sector-conglomerates pharmaceuticals social-media tech-stocks
INCY Q1 Earnings & Revenues Beat Estimates on Higher Product Sales
by Zacks Equity Research
Incyte reports better-than-expected first-quarter 2025 results, beating both earnings and revenue estimates, driven by strong Jakafi and Opzelura sales.
NVSNegative Net Change LLYNegative Net Change BAYRYPositive Net Change INCYNegative Net Change
biotechnology biotechs earnings medical pharmaceuticals
Novo Nordisk Before Q1 Earnings: How Should Investors Play the Stock?
by Ahan Chakraborty
NVO's first-quarter revenues are expected to have been driven by its sales of diabetes and obesity care products, especially Wegovy, Ozempic and Rybelsus.
NVOPositive Net Change LLYNegative Net Change AMGNNegative Net Change VKTXNegative Net Change
biotechnology biotechs earnings-preview medical pharmaceuticals
Novartis Beats on Q1 Earnings and Sales, Raises Guidance, Stock Up
by Zacks Equity Research
NVS' first-quarter earnings and sales beat estimates. Based on the strong momentum of its key drugs, the company raises its annual guidance. Share price rises.
NVSNegative Net Change RHHBYNegative Net Change PFENegative Net Change BAYRYPositive Net Change
biotechnology biotechs earnings medical pharmaceuticals
AZN Q1 Earnings Beat, Stock Down on Soft Sales Performance of Key Drugs
by Zacks Equity Research
AstraZeneca reports mixed first-quarter 2025 results. The fall in pre-market is likely due to the soft sales performance of key drugs across the oncology and rare disease segments.
SNYNegative Net Change AZNPositive Net Change MRKNegative Net Change AMGNNegative Net Change
biotechs earnings medical pharmaceuticals vaccines
3 Unconventional Cannabis Stocks to Watch in 2025
by Sundeep Ganoria
Think cannabis investing is all hype? These three unconventional stocks could change your mind - and your portfolio - in 2025.
PMNegative Net Change JAZZNegative Net Change CRBPNegative Net Change
biotechs marijuana medical pharmaceuticals pot-stocks
The Zacks Analyst Blog Highlights Pfizer, Eli Lilly, Amgen, Biogen and Regeneron
by Zacks Equity Research
Pfizer, Eli Lilly, Amgen, Biogen and Regeneron are included in this Analyst Blog.
REGNNegative Net Change BIIBNegative Net Change PFENegative Net Change LLYNegative Net Change AMGNNegative Net Change
pharmaceuticals
Zacks.com featured highlights StoneCo, Carriage Services, Associated Banc-Corp and Pfizer
by Zacks Equity Research
StoneCo, Carriage Services, Associated Banc-Corp and Pfizer have been highlighted in this Screen of The Week article.
PFENegative Net Change CSVPositive Net Change ASBNegative Net Change STNENegative Net Change
pharmaceuticals
Will These 5 Big Drug Stocks Surpass Q1 Earnings Forecasts?
by Zacks Equity Research
Let's look at five pharma and drug companies, PFE, LLY, AMGN, BIIB and REGN, which are scheduled to release their first-quarter 2025 results later this week.
REGNNegative Net Change BIIBNegative Net Change PFENegative Net Change LLYNegative Net Change AMGNNegative Net Change
biotechs pharmaceuticals
Is Eli Lilly Stock a Portfolio Must-Have Pre-Q1 Earnings? (Revised)
by Kinjel Shah
Investor focus is likely to be on the sales numbers of LLY's tirzepatide medicines Mounjaro and Zepbound.
NVOPositive Net Change LLYNegative Net Change AMGNNegative Net Change VKTXNegative Net Change
pharmaceuticals
BMY Falls 4% Post Q1 Earnings: Should You Buy, Sell or Hold the Stock?
by Ekta Bagri
Bristol Myers' first-quarter performance and raised annual guidance are encouraging. However, we recommend investors to stay on the sidelines as generic competition for legacy drugs and recent pipeline setbacks weigh on the stock.
BMYNegative Net Change PFENegative Net Change MRKNegative Net Change
biotechnology biotechs earnings-report medical pharmaceuticals